Adipose tissue–derived adipsin marks human aging in non-type 2 diabetes population
Authors' conclusion
Our results demonstrate an increase in circulating adipsin in T2D and aging, and it scores as a candidate plasma marker for aging specifically in non-T2D population.
Study context
- Population
- Community health cohort of 353 subjects and hospital cohort of 52 subjects, with and without T2D; OGTT in a subset of 43 patients with T2D
- Outcome
- Association of adipsin (plasma, AT expression, secretion) with insulin secretion, T2D risk factors and aging biomarkers
Methodological detailscommunity cohort, hospital cohort, OGTT substudy
- Community cohort
- Hospital cohort
- OGTT substudy
Main finding
As reported in the abstract
Adipsin associations
- Plasma adipsin had no significant correlation with insulin secretion in people with diabetes
- Among T2D risk factors, adipsin levels independently associated only with age
- Positive correlation between plasma adipsin and age in subjects without T2D was lost in patients with T2D
- Plasma adipsin, adipose tissue (AT) adipsin expression and secretion upregulated in both T2D and aging, with corresponding drop in HOMA of β-cell function
- Adipsin expression positively associated with aging biomarkers β-galactosidase, p21 and p16
- Growth and differentiation factor-15 strongly correlated with adipsin
Observational data: associations, not effects.
Original publication
Adipose tissue–derived adipsin marks human aging in non-type 2 diabetes population. BMJ Open Diabetes Res Care. Published 29 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →